Atea Pharmaceuticals annual current ratio
2019
2020
2021
2022
2023
2024
2025
Atea Pharmaceuticals Current Ratio Growth & History (AVIR)
Atea Pharmaceuticals's current ratio was 7.82 for fiscal 2025.
View full Atea Pharmaceuticals company overviewAtea Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 7.82 | −17.04 | −68.55% |
| 2024 | 2024-12-31 | 24.85 | 6.62 | +36.28% |
| 2023 | 2023-12-31 | 18.24 | −17.53 | −49.01% |
| 2022 | 2022-12-31 | 35.77 | 22.19 | +163.41% |
| 2021 | 2021-12-31 | 13.58 | 10.84 | +396.61% |
| 2020 | 2020-12-31 | 2.73 | −6.26 | −69.61% |
| 2019 | 2019-12-31 | 9.00 | — | — |
Atea Pharmaceuticals quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 8.13 | −11.04 | −57.58% |
| Q1 2026 | 2026-03-31 | 7.89 | −12.06 | −60.45% |
| Q4 2025 | 2025-12-31 | 7.82 | −17.04 | −68.55% |
| Q3 2025 | 2025-09-30 | 16.66 | −2.67 | −13.80% |
| Q2 2025 | 2025-06-30 | 19.17 | 0.14 | +0.75% |
| Q1 2025 | 2025-03-31 | 19.94 | 6.66 | +50.13% |
| Q4 2024 | 2024-12-31 | 24.85 | 6.62 | +36.28% |
| Q3 2024 | 2024-09-30 | 19.33 | −12.60 | −39.47% |
| Q2 2024 | 2024-06-30 | 19.02 | −19.40 | −50.49% |
| Q1 2024 | 2024-03-31 | 13.28 | −37.88 | −74.03% |
| Q4 2023 | 2023-12-31 | 18.24 | −17.53 | −49.01% |
| Q3 2023 | 2023-09-30 | 31.93 | −11.69 | −26.79% |
| Q2 2023 | 2023-06-30 | 38.42 | 10.96 | +39.91% |
| Q1 2023 | 2023-03-31 | 51.16 | 26.23 | +105.22% |
| Q4 2022 | 2022-12-31 | 35.77 | 22.19 | +163.41% |
| Q3 2022 | 2022-09-30 | 43.62 | 40.40 | +1256.00% |
| Q2 2022 | 2022-06-30 | 27.46 | 24.28 | +762.65% |
| Q1 2022 | 2022-03-31 | 24.93 | 21.63 | +654.51% |
| Q4 2021 | 2021-12-31 | 13.58 | 10.84 | +396.61% |
| Q3 2021 | 2021-09-30 | 3.22 | −6.81 | −67.91% |
| Q2 2021 | 2021-06-30 | 3.18 | — | — |
| Q1 2021 | 2021-03-31 | 3.30 | — | — |
| Q4 2020 | 2020-12-31 | 2.73 | −6.26 | −69.61% |
| Q3 2020 | 2020-09-30 | 10.02 | — | — |
| Q4 2019 | 2019-12-31 | 9.00 | — | — |
Atea Pharmaceuticals current ratio trends
Over the last five fiscal years, Atea Pharmaceuticals's current ratio increased from 2.73 to 7.82, a change of 5.08. The latest reported quarter, Q2 2026, shows 8.13.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atea Pharmaceuticals source filings ↗